Drugs & Targets Novartis’s Rydapt gets EU approval for AML and SM indications September 22, 2017Vol.43 No.35
Drugs & Targets FDA approves lower dose of cabazitaxel for prostate cancer September 22, 2017Vol.43 No.35
Drugs & Targets EMA committee issues positive opinion for Tesaro’s Zejula September 22, 2017Vol.43 No.35
Drugs & Targets Opdivo receives Japanese approval for advanced gastric cancer indications September 22, 2017Vol.43 No.35
Drugs & Targets Bayer’s Aliqopa gets FDA accelerated approval for relapsed follicular lymphoma September 15, 2017Vol.43 No.34
Drugs & Targets Cemiplimab receives FDA breakthrough designation for advanced cutaneous squamous cell carcinoma September 15, 2017Vol.43 No.34
Drugs & Targets EC approves Merck’s Keytruda for locally advanced, metastatic urothelial carcinoma September 08, 2017Vol.43 No.33
Drugs & Targets FDA grants orphan drug status to Cellect’s ApoGraft for acute and chronic GvHD September 08, 2017Vol.43 No.33
Drugs & Targets Gazyva in previously untreated follicular lymphoma gets FDA priority review September 01, 2017Vol.43 No.32
